Liberty City Ventures intent to use trademark application filed

Liberty City Ventures intent to use trademark application filed

FDA Announces Public Hearing on CNPV Pilot Program

The FDA is announcing a public hearing on its Commissioner's National Priority Voucher (CNPV) Pilot Program, designed to expedite review times for qualifying new drug applications and biologics license applications. The agency is seeking feedback on program eligibility, selection processes, and review procedures.

FDA Complaint Document

The FDA has posted a complaint document related to its regulatory activities. The document is available for review on the Regulations.gov portal. No specific compliance actions or deadlines are indicated for regulated entities.

FDA CDER Final Response Letter to AdventaPharma DWC-LLC

The FDA's Center for Drug Evaluation and Research (CDER) has issued a final response letter to AdventaPharma DWC-LLC. This document is part of the ongoing regulatory process for drug applications and does not appear to contain new compliance obligations.

FDA CDER Final Response Letter to Rising Pharma Holdings

The FDA's Center for Drug Evaluation and Research (CDER) has issued a final response letter to Rising Pharma Holdings, Inc. The document details the agency's final decision regarding the company's submission. Specific details of the response are contained within the letter.

FDA Completeness Assessment Correspondence

The FDA has posted Completeness Assessment Correspondence related to drug applications. This notice indicates that documents are available for review concerning the completeness of certain regulatory submissions.

FDA Complaint Filed and Closed for Comments

The FDA has filed a complaint related to tobacco products, which is now open for public comment. The complaint was filed on March 23, 2026, and the comment period is active.

FDA CDER Response Letter to Laboflex, Inc.

The FDA's Center for Drug Evaluation and Research (CDER) has issued a response letter to Laboflex, Inc. The document is a final response, indicating a resolution or specific feedback on a matter concerning the company. No further details on the content or specific regulatory actions are available.

FDA Completeness Assessment Correspondence

The FDA has posted Completeness Assessment Correspondence related to drug applications. This notice indicates that specific correspondence documents are available for review, authored by CDER.

Animal Drug User Fees Reporting - Comment Period

The FDA is seeking public comment on proposed information collection provisions related to its animal drug and animal generic drug user fee programs. The comment period is open until May 22, 2026, as required by the Paperwork Reduction Act.